Protalix BioTherapeutics Common Stock

Protalix BioTherapeutics (PLX) currently reports a common stock of $0 as of June 2026. That compares with $80K in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Protalix BioTherapeutics's common stock history and peer comparisons.

Protalix BioTherapeutics's common stock decreased from $80K to $0 — a 100.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Protalix BioTherapeutics reported $0 in common stock as of June 2026. That compares with $80K in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Protalix BioTherapeutics, and consider following PLX for alerts when major investors trade the stock.

Protalix BioTherapeutics is classified in the Healthcare sector. On common stock, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PLX with unrelated industries.